Immunogenicity

Immuno-Oncology: Functional Assays for Immune Checkpoint Inhibitors as Emerging Therapeutics, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, July 12, 2021
Medical specialties, Clinical medicine, Medicine, Cancer immunotherapy, Immune checkpoint, Immunogenicity, Biotechnology, Immunotherapy, Biological engineering, Affimer

This webinar will showcase assays to evaluate cellular pathways of immune cells, T-cells, and macrophages while highlighting functional and immunogenicity assays developed in support of current and emerging therapeutics.

Key Points: 
  • This webinar will showcase assays to evaluate cellular pathways of immune cells, T-cells, and macrophages while highlighting functional and immunogenicity assays developed in support of current and emerging therapeutics.
  • The speakers will outline how in vitro methods mimic the tumor environment to measure therapeutic functionality.
  • For more information, or to register for this event, visit Immuno-Oncology: Functional Assays for Immune Checkpoint Inhibitors as Emerging Therapeutics.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.

Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

Retrieved on: 
Tuesday, July 6, 2021
Medical specialties, Life sciences, Health, Immunology, Biotechnology, Immunogenicity, Vaccines, Biopharmaceutical, ImmunoGen, Glycogen storage disease type II

At the FDA, she oversaw the regulation and approval of numerous protein therapeutics and served as expert consultant to the National Institute of Health's Immune Tolerance Network.

Key Points: 
  • At the FDA, she oversaw the regulation and approval of numerous protein therapeutics and served as expert consultant to the National Institute of Health's Immune Tolerance Network.
  • Amy and I look forward to sharing her vast experience with EpiVax aficionados during our ' Fearless Science World tour ' this fall and winter."
  • Dr. Rosenberg will also work with EpiVax scientists on a range of internal research programs, listed below:
    Personalized Immunogenicity Assessment for Biologics (PIMA): Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease .
  • EpiVax's immunogenicity screening toolkits for therapeutics (ISPRI) and vaccines (iVAX) , are employed in advancing the research of a global roster of companies.

Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

Retrieved on: 
Tuesday, July 6, 2021
Life sciences, Medical specialties, Health, Immunology, Biotechnology, Immunogenicity, Center for Drug Evaluation and Research, ImmunoGen, Food and Drug Administration, Biopharmaceutical, Glycogen storage disease type II

Dr. Amy Rosenberg (Director, FDA CDER) will join EpiVax as Senior Director of Immunology and Protein Therapeutics.

Key Points: 
  • Dr. Amy Rosenberg (Director, FDA CDER) will join EpiVax as Senior Director of Immunology and Protein Therapeutics.
  • At the FDA, she oversaw the regulation and approval of numerous protein therapeutics and served as expert consultant to the National Institute of Health's Immune Tolerance Network.
  • Amy and I look forward to sharing her vast experience with EpiVax aficionados during our ' Fearless Science World tour ' this fall and winter."
  • Dr. Rosenberg will also work with EpiVax scientists on a range of internal research programs, listed below:
    Personalized Immunogenicity Assessment for Biologics (PIMA): Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease .

Treos Bio Announces the Publication of Preclinical Data in Frontiers in Genetics Showing its COVID-19 Peptide Vaccine Mimics the Diversity of T Cell Immunity Produced by Natural SARS-CoV-2 Infection

Retrieved on: 
Monday, June 28, 2021
Medical specialties, Clinical medicine, Medicine, Virotherapy, Immunology, Cancer immunotherapy, Immunotherapy, Vaccine, Immunogenicity

Overall, with the downstream physiological activation shown, these data have compelling implications for the development of highly immunogenic, T cell-focused global vaccines against various pathogens and diseases.

Key Points: 
  • Overall, with the downstream physiological activation shown, these data have compelling implications for the development of highly immunogenic, T cell-focused global vaccines against various pathogens and diseases.
  • We look forward to leveraging our proprietary data science and therapeutic platform to continue investigating this program.
  • This technology aims to address the challenge of the variability of an individual patients clinical responses to cancer immunotherapies.
  • Treos lead candidate is PolyPEPI-1018, an off-the-shelf immunotherapy for the treatment of metastatic colorectal cancer, co-developed with a candidate companion diagnostic.

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®

Retrieved on: 
Wednesday, June 23, 2021
Branches of biology, Virotherapy, Biology, Molecular genetics, Life sciences, RNA, Gene expression, Messenger RNA, Spliceosome, Immunotherapy, Immunogenicity, Viral vector

This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.

Key Points: 
  • This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.
  • "We have already demonstrated that TriMix has a benign safety profile and promotes high mRNA expression levels," comments Steven Powell, CEO, eTheRNA.
  • "TetraMix will now be integrated into our programs to engineer new generation mRNA immunotherapies offering even greater efficacy and immunogenicity."
  • Technologies such as mRNA, lentiviral vectors, and single domain antibodies (better known as nanobodies) are employed for these purposes.

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®

Retrieved on: 
Wednesday, June 23, 2021
Branches of biology, Virotherapy, Biology, Molecular genetics, Life sciences, RNA, Gene expression, Messenger RNA, Spliceosome, Immunotherapy, Immunogenicity, Viral vector

This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.

Key Points: 
  • This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.
  • "We have already demonstrated that TriMix has a benign safety profile and promotes high mRNA expression levels," comments Steven Powell, CEO, eTheRNA.
  • "TetraMix will now be integrated into our programs to engineer new generation mRNA immunotherapies offering even greater efficacy and immunogenicity."
  • Technologies such as mRNA, lentiviral vectors, and single domain antibodies (better known as nanobodies) are employed for these purposes.

Global PEGylated Market (2021 to 2026) - Featuring Celares, Profacgen and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Health, Pharmaceutical, Biotechnology, PEGylation, Pharmacokinetics, Life sciences, Health sciences, Immunogenicity, Health care, Antiviral drugs

PEGylated proteins offer advantages such as extended half-life, reduced toxicity, lower immunogenicity, and increase in proteolytic protection which is accelerating the market growth of PEGylated proteins.

Key Points: 
  • PEGylated proteins offer advantages such as extended half-life, reduced toxicity, lower immunogenicity, and increase in proteolytic protection which is accelerating the market growth of PEGylated proteins.
  • Thus, failures in drug development and rising recalls of the therapeutic drugs might hamper the growth of the PEGylated proteins market during the forecast period.
  • The novel coronavirus pandemic did not adversely affect the PEGylated Proteins Market.
  • The impact of Covid-19, on the PEGylated proteins market was minimal.

HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers

Retrieved on: 
Monday, June 7, 2021
Medical specialties, Immunology, Branches of biology, Clinical medicine, Immunogenicity, ELISPOT, T cell, ImmunoGen, CD8

The company also announced translational data suggesting a relationship between T cell response and potential clinical efficacy.

Key Points: 
  • The company also announced translational data suggesting a relationship between T cell response and potential clinical efficacy.
  • Preliminary data show that HB-200 therapy is highly immunogenic, inducing unprecedented levels of activated, tumor antigen-specific CD8+ T cells.
  • CD8+ T cell immunogenicity was assessed using direct Enzyme-Linked ImmunoSpot (ELISpot) T cell analysis and intracellular cytokine staining (ICS) followed by flow cytometry.
  • The data are from the ongoing Phase 1 dose escalation; the recommended Phase 2 dose for HB-200 therapy has yet not been reached.

Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Life sciences, Immunology, Health care, Health sciences, Biotechnology, Immunogenicity, Biopharmaceutical, Autoimmunity, Trubion

The results were presented today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The results were presented today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Arcellxs proprietary binding domains are novel synthetic proteins engineered for reduced immunogenicity and designed to bind specific therapeutic targets.
  • CART-ddBCMA has been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration.
  • Arcellx is a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.

Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion’s AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine

Retrieved on: 
Thursday, June 3, 2021
Medical specialties, Medicine, Virology, Branches of biology, Medical research, COVID-19 vaccine, Vaccine, Immunogenicity, DNA vaccine, Antigen, Peptide vaccine, Shane Crotty

The AICoV program aims to potentially develop the next generation of corona virus vaccines, utilizing RAVEN, Evaxions AI powered vaccine design platform, along with Evaxions proprietary Antigen Presenting Cell (APC) targeting DNA vaccine technology and novel manufacturing approaches.

Key Points: 
  • The AICoV program aims to potentially develop the next generation of corona virus vaccines, utilizing RAVEN, Evaxions AI powered vaccine design platform, along with Evaxions proprietary Antigen Presenting Cell (APC) targeting DNA vaccine technology and novel manufacturing approaches.
  • The RAVEN platform, an integral part of Evaxions AICoV program, combines advanced algorithms from Evaxions proprietary AI-immunology Core technology to identify optimal T and B cell antigen targets for the development of novel viral vaccines.
  • Early data demonstrate that RAVEN identifies novel immunogenic T cell epitopes outside the spike protein, showing RAVENs potential to rapidly support the design of novel SARS-COV-2 vaccines against current and future variants.
  • In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections currently in preclinical development.